BRIDGEBIO PHARMA INC.

BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)

17 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Announces Pricing of Public Offering of Common Stock

08 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

BridgeBio Pharma Announces Proposed Public Offering of Common Stock

06 Mar 2023 16:05:38 By Nasdaq GlobeNewswire

BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events

06 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023

03 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update

23 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

17 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023

13 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in February and March Investor Events

08 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma to Present at the J.P. Morgan Healthcare Conference

04 Jan 2023 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1

22 Dec 2022 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in November Investor Events

09 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update

03 Nov 2022 07:30:01 By Nasdaq GlobeNewswire

BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Kα:RAS Breaker Mechanism at the Fourth RAS Initiative Symposium

17 Oct 2022 12:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)

14 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society

13 Oct 2022 16:00:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)

11 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium

07 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

20 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in September Investor Events

06 Sep 2022 07:30:00 By Nasdaq GlobeNewswire